Victoza
liraglutide — GLP-1 receptor agonist by Novo Nordisk
GLP-1subcutaneous injectionOnce dailyFDA Approved
Reviewed by Dr. Elena Vance, DOLast reviewed 2 sources cited
FDA-Approved Indications
- Type 2 diabetes mellitus (adjunct to diet and exercise)
- Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
- Type 2 diabetes in patients aged 10+ years
Dosing
| Route | subcutaneous injection |
| Frequency | Once daily |
| Starting Dose | 0.6 mg daily |
| Maintenance | 1.2 mg or 1.8 mg daily |
| Max Dose | 1.8 mg daily |
| Titration | 0.6 mg x 1 week → 1.2 mg. May increase to 1.8 mg if additional glycemic control needed. |
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Nausea | 28% | 2/5 |
| Diarrhea | 17% | 2/5 |
| Vomiting | 11% | 3/5 |
| Headache | 9% | 1/5 |
| Decreased appetite | 9% | 1/5 |
| Dyspepsia | 7% | 2/5 |
| Constipation | 6% | 1/5 |
| Pancreatitis (rare) | <1% | 5/5 |
Cost
| List Price | $950-$1,100/month |
| With Insurance | $25-$150/month (varies by plan) |
| Savings Card | $25/month (Novo Nordisk savings card, commercially insured) |
Pricing last updated 2026-04-14. Actual costs vary by pharmacy, insurance plan, and location.
Compare Victoza With
Boxed Warning
Thyroid C-cell tumors: In rodents, liraglutide causes thyroid C-cell tumors. It is unknown whether liraglutide causes thyroid C-cell tumors in humans.
Sources
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.